Background and Objectives
Patient reported outcomes (PROs) are used in various contexts for a variety of purposes (Figure 1 ). For example, while PRO questionnaires can be used to substantiate treatment efficacy hypotheses in product approval efforts, there is value in the use of PROs to promote disease awareness, facilitate clinical intervention and discourse between patients and healthcare providers, monitoring change in health status over time, and informing patientcentered treatment decisions. Challenges that outcomes researchers face in this regard are the identification, development, and/or implementation of PRO questionnaires to accommodate these multiple contexts of use as each context may have unique measurement requirements. The purpose of this poster is to provide suggestions and an example of how outcomes researchers might approach simultaneous development of a PRO questionnaire for use in two unique contexts -clinical trials to evaluate efficacy claims and in clinical settings to facilitate patientprovider discussions.
Study Overview
To illustrate the types of methodological and scientific considerations to be made during simultaneous PRO questionnaire development, the following example is provided:
 A set of research activities were undertaken to develop a PRO questionnaire to evaluate the primary signs and symptoms of chronic plaque psoriasis, for use in clinical trial and real-world settings.
 Specifically, development of the Self-Assessment of Psoriasis Symptoms-Clinical Trial (SAPS-CT) and SAPS-Real World (SAPS-RW) questionnaires was informed by the following: a) literature review, expert advice meetings, patient concept elicitation interviews; b) concept selection and questionnaire construction; c) content evaluation; and d) and psychometric evaluation.
 Given the multiple contexts of use intended for the questionnaire, instrument developers created distinct, albeit corresponding questionnaires paying close attention to content, response options, recall period, focus of measurement (e.g., symptom at its worst vs. symptom on average), and number of items.
 The specific questionnaire development methods are described below and summarized in Figure 2 along with key simultaneous questionnaire development considerations.
Methods

STAGE 1: CONCEPT GENERATION
 Generation of sign and symptom concepts for each version of the PRO questionnaire were identified from the following three sources:
 Literature Review: MEDLINE® was queried using search terms for psoriasis and its synonyms, as well as terms for signs, symptoms, and natural history. The search was limited to English-language studies in humans that had been published in the 12 years prior to the search.
 Expert meetings: Consultative meetings were conducted with US-based dermatologists (N=3) where trained meeting facilitators elicited expert perspectives on the signs and symptoms of chronic plaque psoriasis. These meetings were audio-recorded, transcribed, anonymized, and coded via ATLAS.ti version 7.1.5. Qualitative analysis entailed review of transcripts to identify common signs and symptoms of chronic plaque psoriasis.
 Concept elicitation interviews: Face-to-face interviews were conducted with adult subjects with clinically confirmed chronic plaque psoriasis (N=60). Interviewers utilized a semi-structured interview guide to elicit subjects' descriptions of their signs and symptoms. All interviews were audio-recorded, transcribed, anonymized, and coded via ATLAS.ti version 7.1.5. Qualitative analysis was conducted in a similar manner as described for the expert meetings. Saturation was assessed by creating a saturation grid to compare the amount of novel information that was observed across the first 40 interviews.
STAGE 2: CONCEPT SELECTION AND QUESTIONNAIRE CONSTRUCTION
 Sign and symptom-level concepts to be assessed via the newly-constructed psoriasis PRO questionnaires were selected based on harmonized findings from the three concept generation activities.
 The structure and format, including item phrasing, order of items, response options, and recall period were determined for each version of the questionnaire.
 Once constructed, a dermatological expert evaluated the targeted measurement concepts.
 Two versions of the SAPS questionnaire were constructed, which were based on each instrument's context of use.
STAGE 3: CONTENT EVALUATION
 Subjects with clinically confirmed chronic plaque psoriasis (N=20) participated in cognitive debriefing interviews, where their ability to read, understand, and complete the SAPS was evaluated.

Interviewers asked subjects open-ended questions about their experiences with chronic plaque psoriasis to confirm the content of the SAPS and then subjects were asked to complete the SAPS-CT and provide feedback on the instructions, items, recall period, and response options. Subjects were also asked to complete and provide feedback on an additional item from the SAPS-RW, specifically to evaluate the use of an alternative recall period ("the past 7 days" instead of "the past 24 hours").
 Interviews were audio-recorded, transcribed verbatim, anonymized, imported and qualitatively coded via ATLAS.ti version 7.1.5, and analyzed.
 Based on the content evaluation of the SAPS, the questionnaires were modified.
STAGE 4: PSYCHOMETRIC EVALUATION
 A prospective, non-interventional study was conducted in the US amongst adults with clinically confirmed chronic plaque psoriasis to evaluate the scores produced by the SAPS-CT and SAPS-RW.
 Using pen-and-paper administrations, clinicians and subjects completed several questionnaires across multiple timepoints:  Preliminary analysis: SAS version 9.2 (SAS Institute, Cary NC) and MPlus version 6.8. were utilized in a preliminary analysis used to inform item reduction of the questionnaires: acceptability and compliance, item and scale distribution, inter-item correlations, exploratory factor analysis (EFA), Item Response Theory-Graded Response Model (IRT-GRM) and exploratory internal consistency analyses.
 Item Reduction: Reduction of items for both the SAPS-CT and -RW was conducted based on both the quantitative and the previously conducted qualitative research.
 Psychometric evaluation: Following item reduction, estimates from the following tests were generated: reliability (internal consistency and test-retest reliability), and construct validity (convergent and discriminant validity correlation estimates, and a set of known-groups analyses based on the PASI, PGI-S, and PGA).
Conclusions
Given the importance of understanding the patient experience in a variety of contexts, there is immense value for PRO questionnaires beyond product labeling. Though not without challenges, with careful planning and consideration outcomes researchers can create significant efficiencies by simultaneously developing and evaluating PRO questionnaires that are fit for multiple purposes across the drug development and post-marketing lifecycle. When approaching simultaneous development of questionnaires suitable for use in clinical trials to evaluate treatment efficacy hypotheses and in 'real world' clinical settings to facilitate patient-provider discussions, outcomes researchers should consider both the similarities and differences in the concepts of measurement (comparing comprehensiveness of measurement versus burden of administration), the focus of measurement (e.g., symptom at its worst versus symptoms on average), applicability of recall period, and appropriateness of response options. 
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STAGE 2: CONCEPT SELECTION AND QUESTIONNAIRE CONSTRUCTION
 Taking into consideration the requirements in the FDA PRO Guidance for the development of PRO measures 1 and the respective intended contexts of use, the following concepts were selected for measurement for each version of the SAPS: pain, itching, redness, scaling, flaking, dry skin, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain (Table 1 ).
 Developers agreed that both versions of SAPS would be pen-paper based, with an 11-point numeric rating scale (NRS) ranging from "No (sign/symptom)" to "Worst possible (sign/symptom); it was decided that given the target context of use in regulated clinical trials the SAPS-CT should prompt respondents to rate their symptom "at its worst" in the 24 hours prior to assessment, while respondents are prompted to rate their symptoms "on average" in the seven days prior to assessment in the SAPS-RW version to accommodate administration in a clinical setting.
STAGE 3: CONTENT EVALUATION
 Of the 20 subjects (range = 20.9-77.9, mean age = 44.9, SD = 17.0 years) who participated in the cognitive debriefing interviews, 55% (n=11) were female, and most were white/Caucasian (n=13, 65.0%) or black/African American (n=3, 15.0%), employed full time (n=11, 55.0%), having college/university degree or less (n=15, 75.0%), and having mild (n=13, 65.0%) chronic plaque psoriasis (self-rated).
 Upon completion of the cognitive interviews, the following revisions were made:  Item 5 (flaking) was revised to further clarify the meaning of the concept;  Item 6 (dry skin) was deleted based on conceptual overlap with several other items and patients' difficulty understanding the item concept; and  Item 12 (joint pain) was revised to further clarify where this symptom could be experienced.  Subjects reported no difficulty interpreting the single example item from the SAPS-RW as intended.
STAGE 4: PSYCHOMETRIC EVALUATION
 Of the 200 subjects (range = 18.3 -65.9, mean age = 45.6, SD = 12.8 years) in the observational study, 50% (n=100) were female, and most were white/Caucasian 134 (67.0%) or black/African American 30 (15.0%), employed full time (n=113, 56.5%), having college/university degree or less (n=184, 92.0%). Clinicians reported subjects' plaque psoriasis severity as mild (n=64, 32.0%), moderate (n=79, 39.5%) and severe (n=57, 28.5%).
 The SAPS-CT and -RW showed good quality of completion and, overall, the responses were well distributed among the response options. No notable ceiling effects were observed; however, floor effects were found for certain items in each version of the questionnaire.
 Based on preliminary analyses and with consideration for the intended context of use for each questionnaire, the SAPS-RW was reduced to six items (overall pain, itching, redness, scaling, bleeding, and joint pain) to ease patient burden in a clinical setting and the SAPS-CT was reduced to nine items (overall pain, itching, redness, scaling, bleeding, burning, tenderness, cracking/pain, and joint pain) for comprehensive evaluation in a clinical trial setting.
 The scores of the SAPS-RW and SAPS-CT were psychometrically evaluated and both showed strong internal consistency reliability, test-retest reliability and construct related validity:
 Internal consistency reliability: SAPS-CT (α=0.956 and 0.967, Timepoint 1 and 2, respectively); SAPS=RW (α=0.926 and 0.943, Timepoint 1 and 8, respectively) ( Table 2) .
 Test-retest reliability: Intra-class correlation coefficients (ICC)= 0.921 and 0.853 for the SAPS-CT and -RW, respectively (Table 2) .
 Construct-related validity:  Correlational analysis with other PRO instruments (the CLCI and DLQI) supported the convergent and discriminant validity of the SAPS-CT and -RW scores (results not presented).
 Known-groups methods demonstrated the SAPS-CT and -RW were able to differentiate among clinically distinct groups (i.e., as clinically distinct groups were considered more severe, SAPS-CT and -RW scores also increased in severity-a monotonic trend) (Table 3) . The overall PASI score ranges from 0-72 with higher scores associated with greater psoriasis severity. Severity ranking was revised to mild: 0-6, moderate: 7-15, severe: >15 as one of the severity groups had less than 25% (criteria indicated in the SAP; **Total scores on a 0-10 scale with higher score indicating worsening symptoms. Only subjects with a score of "no change" PGI-C at Visit 8 as well as a completed PRO at both visits were included in the analysis. * Only concepts selected for the initial versions of the SAPS (i.e., before content evaluation) are presented in the table; **Prior to content evaluation of the SAPS, subjects were asked open-ended questions about their experiences with chronic plaque psoriasis and concepts pertaining to signs and symptoms were identified and tallied; ‡ Burning and stinging were originally classified as a single concept (and has been presented as such), though were later delineated into separate concepts. 
Stage of Simultaneous
